Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its drug limaprost. This therapeutic drug targets analgesia and microcirculation, addressing a significant health issue among the country’s population.
Lumbar Spinal Stenosis: A Prevalent Condition
Tubular stenosis, particularly lumbar spinal stenosis, is one of the most common diseases affecting middle-aged and elderly individuals in China. It afflicts over 30 million people annually. Patients suffering from lumbar spinal stenosis experience blood circulation disorders when the lumbar nerve tissue is compressed. This leads to symptoms such as long-term recurrent lower back pain, leg pain, numbness and weakness, and intermittent claudication.
Limaprost: A Promising Treatment Option
Limaprost, a synthetic derivative of prostaglandin E1, boasts multiple pharmacological effects. It improves peripheral circulatory disturbances, increases blood flow to nerve tissue, alleviates hyperalgesia, and enhances nerve function. As a result, it has demonstrated a good therapeutic effect on patients with lumbar spinal stenosis. Notably, limaprost is the only small-molecule chemical drug in China that is clearly indicated for the treatment of lumbar spinal stenosis, offering a unique solution for this prevalent condition.-Fineline Info & Tech
